Type 1 regulatory T cells (Tr1s) are an inducible subtype of regulatory T cells that can play a beneficial (autoimmune diseases, allergy, hematological malignancies) or detrimental role (some solid tumors and infectious diseases) in human diseases. Tr1 cells.
Researchers at Stanford have developed a novel deep-learning-based tool called CytoTRACE2 that interprets single-cell RNA sequencing (scRNA-seq) to enable the discovery of regenerative cells across all tissue types and novel targets in cancer and other diseases.
Researchers at Stanford have found that a vaccine, enhanced with adjuvants that imprint an antiviral state on innate immune cells and non-hematopoietic organ cells, could confer lasting nonspecific protection against diverse pathogens.
Pharmacologic agents are commonly used to treat psychiatric diseases. These compounds, however, react differently across patients, are often followed by negative side effects and can have varied efficacy timeframes.
Stanford researchers have developed a next-generation protein sequencing platform capable of identifying all the proteins in a cell at single amino acid resolution.
Stanford scientists have developed a novel method to accelerate the development of T cell target probes known as Rapid Identification of Peptide-ligands from Protein Antigen (RIPPA).
SparseGMM, is a new algorithm which is a novel statistical approach for identifying drug targets in cancer patients and other diseases by more accurately modeling biological pathways.
Researchers at Stanford have developed AgeIndex, the first whole-genome epigenetic aging index and method based on Whole Genome Bisulfite Sequencing (WGBS) assays.
Stanford researchers in the Mahajan Lab have created a customizable proteomics platform that can identify protein biomarkers to differentiate among ischemic eye diseases and identify novel therapeutic targets to treat them.